These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37651467)

  • 21. In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance.
    Zhu Y; Yurgelonis I; Noell S; Yang Q; Guan S; Li Z; Hao L; Rothan H; Rai DK; McMonagle P; Baniecki ML; Greasley SE; Plotnikova O; Lee J; Nicki JA; Ferre R; Byrnes LJ; Liu W; Craig TK; Steppan CM; Liberator P; Soares HD; Allerton CMN; Anderson AS; Cardin RD
    Sci Adv; 2024 Jul; 10(30):eadl4013. PubMed ID: 39047088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of SARS-CoV-2 M
    Đukić I; Kaličanin N; Sencanski M; Pajovic SB; Milicevic J; Prljic J; Paessler S; Prodanović R; Glisic S
    Front Biosci (Landmark Ed); 2023 Jan; 28(1):8. PubMed ID: 36722278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upgrading nirmatrelvir to inhibit SARS-CoV-2 Mpro via DeepFrag and free energy calculations.
    Tam NM; Nguyen TH; Pham MQ; Hong ND; Tung NT; Vu VV; Quang DT; Ngo ST
    J Mol Graph Model; 2023 Nov; 124():108535. PubMed ID: 37295158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depicting the inhibitory potential of polyphenols from
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir.
    Yang KS; Leeuwon SZ; Xu S; Liu WR
    J Med Chem; 2022 Jul; 65(13):8686-8698. PubMed ID: 35731933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay.
    Narayanan A; Narwal M; Majowicz SA; Varricchio C; Toner SA; Ballatore C; Brancale A; Murakami KS; Jose J
    Commun Biol; 2022 Feb; 5(1):169. PubMed ID: 35217718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach.
    Havranek B; Demissie R; Lee H; Lan S; Zhang H; Sarafianos S; Ayitou AJ; Islam SM
    J Chem Inf Model; 2023 Nov; 63(22):7180-7188. PubMed ID: 37947496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.
    Sasi VM; Ullrich S; Ton J; Fry SE; Johansen-Leete J; Payne RJ; Nitsche C; Jackson CJ
    Biochemistry; 2022 Nov; 61(22):2495-2505. PubMed ID: 36326185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Discovery of SARS-CoV-2 main protease inhibitors using an optimized FRET-based high-throughput screening assay].
    Yan G; Li D; Qi H; Fu Z; Liu X; Zhang J; Chen Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2236-2249. PubMed ID: 35786475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
    Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
    Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AI-Driven Discovery of SARS-CoV-2 Main Protease Fragment-like Inhibitors with Antiviral Activity
    Saramago LC; Santana MV; Gomes BF; Dantas RF; Senger MR; Oliveira Borges PH; Ferreira VNDS; Dos Santos Rosa A; Tucci AR; Dias Miranda M; Lukacik P; Strain-Damerell C; Owen CD; Walsh MA; Ferreira SB; Silva-Junior FP
    J Chem Inf Model; 2023 May; 63(9):2866-2880. PubMed ID: 37058135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into the mechanism of SARS-CoV-2 main protease autocatalytic maturation from model precursors.
    Aniana A; Nashed NT; Ghirlando R; Coates L; Kneller DW; Kovalevsky A; Louis JM
    Commun Biol; 2023 Nov; 6(1):1159. PubMed ID: 37957287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond.
    de Oliveira VM; Ibrahim MF; Sun X; Hilgenfeld R; Shen J
    Res Sq; 2022 Aug; ():. PubMed ID: 35982654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition.
    Dey-Rao R; Smith GR; Timilsina U; Falls Z; Samudrala R; Stavrou S; Melendy T
    Antiviral Res; 2021 Nov; 195():105183. PubMed ID: 34626674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 main protease inhibitors: What is moving in the field of peptides and peptidomimetics?
    Algar-Lizana S; Bonache MÁ; González-Muñiz R
    J Pept Sci; 2023 May; 29(5):e3467. PubMed ID: 36479966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
    Ullrich S; Ekanayake KB; Otting G; Nitsche C
    Bioorg Med Chem Lett; 2022 Apr; 62():128629. PubMed ID: 35182772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease.
    Clayton J; de Oliveira VM; Ibrahim MF; Sun X; Mahinthichaichan P; Shen M; Hilgenfeld R; Shen J
    J Chem Inf Model; 2023 Jun; 63(11):3521-3533. PubMed ID: 37199464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of optically active SARS-CoV-2 Mpro inhibitor drug nirmatrelvir (Paxlovid): an approved treatment of COVID-19.
    Ghosh AK; Yadav M
    Org Biomol Chem; 2023 Jul; 21(28):5768-5774. PubMed ID: 37293830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoprocessing and oxyanion loop reorganization upon GC373 and nirmatrelvir binding of monomeric SARS-CoV-2 main protease catalytic domain.
    Nashed NT; Kneller DW; Coates L; Ghirlando R; Aniana A; Kovalevsky A; Louis JM
    Commun Biol; 2022 Sep; 5(1):976. PubMed ID: 36114420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
    Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
    Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.